These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11112870)

  • 1. Risk factors for an early increase in dose of vasoactive agents for intracavernous pharmacotherapy.
    Kim SC; Seo KK; Park BD; Lee SW
    Urol Int; 2000; 65(4):204-7. PubMed ID: 11112870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
    Engel JD; McVary KT
    Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 4. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracavernous chlorpromazine versus phentolamine: a double-blind clinical comparative study.
    Shamloul R; El-Dakhly M; Ghanem H; Gadallah A; Mokhtar H
    J Sex Med; 2004 Nov; 1(3):310-3. PubMed ID: 16422961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Complications of intracavernous pharmacologic infusion in impotence. Long-term results].
    Pastorini S; Marino G; Cocimano V; Griffa D; Pugno E
    Minerva Urol Nefrol; 1993 Sep; 45(3):109-12. PubMed ID: 8278876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1.
    Seyam R; Mohamed K; Akhras AA; Rashwan H
    Int J Impot Res; 2005; 17(4):346-53. PubMed ID: 15772683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
    Floth A; Schramek P
    J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
    Moemen MN; Hamed HA; Kamel II; Shamloul RM; Ghanem HM
    Int J Impot Res; 2004 Apr; 16(2):143-5. PubMed ID: 15014552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intracavernous pharmacotherapy.
    Sidi AA
    Urol Clin North Am; 1988 Feb; 15(1):95-101. PubMed ID: 2449756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction].
    Ribé N; Rajmil O; Bassas L; Jurado C; Pomerol JM
    Arch Esp Urol; 2001 May; 54(4):355-9. PubMed ID: 11455770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis.
    Elhanbly S; Schoor R; Elmogy M; Ross L; Hegazy A; Niederberger C
    J Urol; 2002 Jan; 167(1):192-6. PubMed ID: 11743303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3 years' experience with intracavernous auto-injection therapy].
    Weiske WH
    Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Priapism induced by intracavernous injection].
    Morales Concepción JC
    Arch Esp Urol; 1992 Oct; 45(8):793-5. PubMed ID: 1466580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An improved vasoactive drug combination for a pharmacological erection program.
    Bennett AH; Carpenter AJ; Barada JH
    J Urol; 1991 Dec; 146(6):1564-5. PubMed ID: 1719248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intracavernous pharmacotherapy for organic impotence in the elderly].
    Richter S; Shalev M; Nissenkorn I
    Harefuah; 1990 Aug; 119(3-4):66-7. PubMed ID: 2227669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intracavernous auto-injection therapy with papaverine phentolamine via an auto-injection pen for patients with an erectile dysfunction: similar results achieved in family practice and urology].
    de Boer BJ; Lycklama a Nijeholt AA; Kleinjans HA
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):783-7. PubMed ID: 11346917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.